HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China national free antiretroviral treatment program, 2010-12: A retrospective observational cohort study

The Lancet Infectious Diseases

Volumn 14, Issue 11, 2014, Pages 1065-1072

  Zhang, Fujie ^a,b   Zhu, Hao ^c   Wu, Yasong ^a   Dou, Zhihui ^a   Zhang, Yao ^a   Kleinman, Nora ^c,d   Bulterys, Marc ^c,f   Wu, Zunyou ^a   Ma, Ye ^a   Zhao, Decai ^a   Liu, Xia ^a   Fang, Hua ^a   Liu, Jing ^b   Cai, Wei Ping ^e   Shang, Hong ^b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b The First Affiliated Hospital of China Medical University   (China)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Association of Schools and Programs of Public Health   (United States)

^e Department of Infectious Diseases Guang Zhou Eighth People's Hospital   (China)

^f NAVAL MEDICAL CENTER SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHINA; COHORT ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; VIRUS LOAD; ADOLESCENT; AGED; COINFECTION; COMPLICATION; EPIDEMIOLOGY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHINA; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84908280092     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)70946-6     Document Type: Article

References (48)

1. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ HIV-HBV coinfection-a global challenge. N Engl J Med 2012, 366:1749-1752.
2. Shepard CW, Finelli L, Alter MJ Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5:558-567.
3. Easterbrook P, Sands A, Harmanci H Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis 2012, 32:147-157.
4. Global report: UNAIDS report on the global AIDS epidemic 2012 UNAIDS, (accessed Aug 26, 2014). http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_with_annexes_en.pdf.
5. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010, 14:e1024-e1031.
6. Rockstroh JK, Spengler U HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004, 4:437-444.
7. Taylor LE, Swan T, Mayer KH HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis 2012, 55(suppl 1):S33-S42.
8. Weinbaum CM, Sabin KM, Santibanez SS Hepatitis B, hepatitis C, and HIV in correctional populations: a review of epidemiology and prevention. AIDS 2005, 19(suppl 3):S41-S46.
9. Kim JH, Psevdos G, Suh J, Sharp VL Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. World J Gastroenterol 2008, 14:6689-6693.
10. Hoffmann CJ, Thio CL Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 2007, 7:402-409.
11. Sulkowski MS Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353-367.
12. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
13. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010, 376:449-457.
14. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006, 368:505-510.
15. Thio CL, Seaberg EC, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.
16. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006, 166:1632-1641.
17. Nunez M Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010, 52:1143-1155.
18. Labarga P, Soriano V, Vispo ME, et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196:670-676.
19. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19:593-601.
20. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
21. Stebbing J, Waters L, Mandalia S, Bower M, Nelson M, Gazzard B Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005, 41:906-911.
22. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356:1800-1805.
23. Sheng WH, Chen MY, Hsieh SM, et al. Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. Clin Infect Dis 2004, 38:1471-1477.
24. Anderson KB, Guest JL, Rimland D Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004, 39:1507-1513.
25. Zhou J, Dore GJ, Zhang F, Lim PL, Chen YM Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007, 22:1510-1518.
26. Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study. Lancet Infect Dis 2011, 11:516-524.
27. Zhang F, Dou Z, Ma Y, et al. Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med 2009, 151:241-251.
28. Mao Y, Wu Z, Poundstone K, et al. Development of a unified web-based national HIV/AIDS information system in China. Int J Epidemiol 2010, 39(suppl 2):79-89.
29. Zhang F China Free Antiretroviral Therapy Manual 2012, People's Medical Publishing House, Beijing. 2012 edn.
30. Antiretroviral therapy for HIV infection in adults and adolescents WHO, (accessed Aug 26, 2014). http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf?ua=1.
31. Ma Y, Zhao D, Yu L, et al. Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China. Clin Infect Dis 2010, 50:264-271.
32. Wang H, Li Y, Zhang C, et al. Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort. AIDS 2012, 26:1755-1763.
33. Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis Co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004, 18:1169-1177.
34. Miailhes P, Trabaud MA, Pradat P, et al. Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007, 45:624-632.
35. Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010, 53:388-396.
36. Landes M, Newell ML, Barlow P, et al. Hepatitis B or hepatitis C coinfection in HIV-infected pregnant women in Europe. HIV Med 2008, 9:526-534.
37. Dou Z, Chen RY, Wang Z, et al. HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008. PLoS One 2010, 5:e13737.
38. Weis N, Lindhardt BO, Kronborg G, et al. Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis 2006, 42:1481-1487.
39. Lumbreras B, Jarrin I, del Amo J, et al. Impact of hepatitis C infection on long-term mortality of injecting drug users from 1990 to 2002: differences before and after HAART. AIDS 2006, 20:111-116.
40. Puoti M, Cozzi-Lepri A, Paraninfo G, et al. Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. Antivir Ther 2006, 11:567-574.
41. Zhu H, Napravnik S, Eron J, et al. Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010. PLoS One 2012, 7:e39414.
42. Liu E, Rou K, McGoogan JM, et al. Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China. J Infect Dis 2013, 208:442-453.
43. Opaleye OO, Oluremi AS, Atiba AB, et al. Occult hepatitis B virus infection among HIV positive patients in Nigeria. J Trop Med 2014, 2014:796121.
44. Khamduang W, Ngo-Giang-Huong N, Gaudy-Graffin C, et al. Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women. Clin Infect Dis 2013, 56:1704-1712.
45. Liao XW, Ling Y, Li XH, et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther 2011, 16:141-147.
46. Zhu H, Napravnik S, Eron JJ, et al. Decreasing excess mortality of HIV-infected patients initiating antiretroviral therapy: comparison with mortality in general population in China, 2003-2009. J Acquir Immune Defic Syndr 2013, 63:e150-e157.
47. Rong-Rong Y, Xi-En G, Shi-Cheng G, Yong-Xi Z Interaction of hepatitis B and C viruses in patients infected with HIV. J Acquir Immune Defic Syndr 1999, 48:505-506.
48. Zhuang X, Liang Y, Chow EP, Wang Y, Wilson DP, Zhang L HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. BMC Infect Dis 2012, 12:130.